Table 1.
Demographic and clinical data of the three groups of patients: KD, MIS-C and AC19.
| KD (n = 9) | MIS-C (n = 20) | AC19 (n = 10) | p | ||
|---|---|---|---|---|---|
| Ethnicity, n (%) | Caucasian | 8 (88.9%) | 18 (90%) | 8 (80%) | n.s. |
| Asian | 1 (11.1%) | 0 (0%) | 2 (20%) | n.s. | |
| Black | 0 (0%) | 2 (10%) | 0 (0%) | n.s. | |
| Sex, n (%) | Male | 3 (33.3%) | 11 (55%) | 5 (50%) | n.s. |
| Female | 6 (66.7%) | 9 (45%) | 5 (50%) | n.s. | |
| Age in months, median (IQR) | 22 (7.4–29) * | 95 (69.8–115.6) * | 26.5 (10.5–157.8) | <0.001 | |
| Respiratory symptoms, n (%) | 1 (11.1%) | 6 (30%) | 5 (50%) | n.s. | |
| Conjunctivitis, n (%) | 9 (100%) *† | 12 (60%) *‡ | 1 (10%) †‡ | <0.001 | |
| Extremity changes, n (%) | 5 (55.6%) | 6 (30%) | 1 (10%) | n.s. | |
| Rash, n (%) | 9 (100%) *† | 11 (55%) *‡ | 1 (10%) †‡ | <0.001 | |
| Oral changes, n (%) | 6 (66.7%) | 12 (60%) | 3 (30%) | n.s. | |
| Cervical lymphadenopathy, n (%) | 7 (77.8%) *† | 3 (15%) * | 2 (20%) † | 0.002 | |
| Abdominal involvement, n (%) | 6 (66.7%) | 17 (85.0%) ‡ | 2 (20%) ‡ | 0.002 | |
| Hypotension, n (%) | 0 * | 11 (55%) *‡ | 0 *‡ | 0.001 | |
| Total days of fever, median (IQR) | 9.0 (5.5–13.0) | 6.0 (4.0–9.0) | - | n.s. | |
| Length of stay, median (IQR) | 8.0 (6.5–15.0) | 10.0 (8.0–13.0) | - | n.s. | |
| Day of standard treatment, median (IQR) | 8.5 (5.3–9.0) * | 5.0 (4.0–6.0) * | - | 0.006 | |
| Non-responders, n (%) | 3 (33.3%) | 5 (25%) | - | n.s. | |
| Inotropic therapy, n (%) | 1 (11.1%) * | 11 (55%) * | - | 0.017 | |
| Respiratory support, n (%) | 0 | 5 (25%) | 0 | n.s. | |
KD stands for Kawasaki Disease; MIS-C stands for Multisystem Inflammatory Syndrome in Children; AC19 stands for acute COVID-19; * stands for statistically significant difference between KD and MIS-C; † stands for statistically significant difference between KD and AC19; ‡ stands for statistically significant difference between MIS-C and AC19. n.s. stands for not significant.